PMID- 26302059
OWN - NLM
STAT- MEDLINE
DCOM- 20160812
LR  - 20151020
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 765
DP  - 2015 Oct 15
TI  - Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis 
      in rats.
PG  - 307-15
LID - S0014-2999(15)30197-7 [pii]
LID - 10.1016/j.ejphar.2015.08.026 [doi]
AB  - Rheumatoid arthritis (RA) is a challenging autoimmune disorder, whose treatments 
      usually cause severe gastrointestinal, renal and other complications. We aimed to 
      evaluate the beneficial anti-arthritic effects of an angiotensin converting 
      enzyme (ACE) inhibitor, ramipril and a dopamine receptor blocker, haloperidol, on 
      Complete Freund's Adjuvant-induced RA in adult female albino rats. Rats were 
      allocated into a normal control group, an arthritis control group, two reference 
      treatment groups receiving dexamethasone (1.5 mg/kg/day) and methotrexate (1 
      mg/kg/day), and two treatment groups receiving ramipril (0.9 mg/kg/day) and 
      haloperidol (1 mg/kg/day). Serum rheumatoid factor, matrix metalloprotinease-3 
      (MMP-3) and cartilage oligomeric matrix protein as specific rheumatoid 
      biomarkers, serum immunoglobulin G and antinuclear antibody as immunological 
      biomarkers, serum tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10) 
      as immunomodulatory cytokines, serum myeloperoxidase and C-reactive protein as 
      inflammatory biomarkers, as well as malondialdehyde and glutathione reduced (GSH) 
      as oxidative stress biomarkers were assessed. A histopathological study on joints 
      and spleens was performed to support the results of biochemical estimations. 
      Ramipril administration significantly corrected all the measured biomarkers, 
      being restored back to normal levels except for MMP-3, TNF-alpha and IL-10. 
      Haloperidol administration restored all the measured biomarkers back to normal 
      levels except for TNF-alpha, IL-10 and GSH. In conclusion, ACE inhibitors represented 
      by ramipril and dopamine receptor blockers represented by haloperidol may 
      represent new promising protective strategies against RA, at least owing to their 
      immunomodulatory, anti-inflammatory and antioxidant potentials.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Fahmy Wahba, Mariam Gamal
AU  - Fahmy Wahba MG
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, 
      Beni-Suef, Egypt.
FAU - Shehata Messiha, Basim Anwar
AU  - Shehata Messiha BA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef 
      University, Beni-Suef, Egypt. Electronic address: drbasimanwar2006@yahoo.com.
FAU - Abo-Saif, Ali Ahmed
AU  - Abo-Saif AA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, 
      Beni-Suef, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20150821
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cartilage Oligomeric Matrix Protein)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - J6292F8L3D (Haloperidol)
RN  - L35JN3I7SJ (Ramipril)
SB  - IM
MH  - Animals
MH  - Antirheumatic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Arthritis, Experimental/*drug therapy/immunology/pathology
MH  - Arthritis, Rheumatoid/*drug therapy/immunology/pathology
MH  - Biomarkers/blood
MH  - Cartilage Oligomeric Matrix Protein/blood
MH  - Female
MH  - Haloperidol/administration & dosage/pharmacology/*therapeutic use
MH  - Interleukin-10/blood
MH  - Matrix Metalloproteinase 3/blood
MH  - Ramipril/administration & dosage/pharmacology/*therapeutic use
MH  - Rats
MH  - Rheumatoid Factor/blood
MH  - Tumor Necrosis Factor-alpha/blood
OTO - NOTNLM
OT  - Dexamethasone
OT  - Haloperidol
OT  - Methotrexate
OT  - Ramipril
OT  - Rat
OT  - Rheumatoid arthritis
EDAT- 2015/08/25 06:00
MHDA- 2016/08/16 06:00
CRDT- 2015/08/25 06:00
PHST- 2015/05/19 00:00 [received]
PHST- 2015/08/04 00:00 [revised]
PHST- 2015/08/17 00:00 [accepted]
PHST- 2015/08/25 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
AID - S0014-2999(15)30197-7 [pii]
AID - 10.1016/j.ejphar.2015.08.026 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2015 Oct 15;765:307-15. doi: 10.1016/j.ejphar.2015.08.026. Epub 
      2015 Aug 21.